Q4 FY2025 Earnings
Financial report interval: 2025.10.01 - 2025.12.31
Overview: Day One Biopharmaceuticals(DAWN) the Revenue is 53.72 M (+83.92%);the EBIT is -27.46 M (+57.97%);the EPS is -0.21 (+67.22%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.05B83.92%
----
----
EBIT
-0.03B57.97%
----
----
EPS
-0.210367.22%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf